The transcription factor c-MYC regulates a multiplicity of genes involved in cellular growth, proliferation, metabolism and DNA damage response and its overexpression is a hallmark of many tumours. Since MYC promotes apoptosis under conditions of stress, such as limited availability of nutrients or cytokines, MYC-driven cells are very much dependent on signals that inhibit cell death. Stress signals trigger apoptosis via the pathway regulated by opposing fractions of the BCL-2 protein family and previous genetic studies have shown that the development of B lymphoid tumours in Eµ-Myc mice is critically dependent on expression of pro-survival BCL-2 relatives MCL-1, BCL-W and, to a lesser extent, BCL-XL, but not BCL-2 itself, and that sustained growth of these lymphomas is dependent on MCL-1. Using recently developed mice that lack expression of all three functional pro-survival A1 genes, we show here that the kinetics of lymphoma development in Eµ-Myc mice and the competitive repopulation capacity of Eµ-Myc haemopoietic stem and progenitor cells is unaffected by the absence of A1. However, conditional loss of a single remaining functional A1 gene from transplanted A1-a−/−A1-bfl/flA1-c−/− Eµ-Myc lymphomas slowed their expansion, significantly extending the life of the transplant recipients. Thus, A1 contributes to the survival of malignant Eµ-Myc-driven B lymphoid cells. These results strengthen the case for BFL-1, the human homologue of A1, being a valid target for drug development for MYC-driven tumours.
c-MYC (hereafter MYC), a basic helix–loop–helix leucine zipper transcription factor that regulates a multiplicity of genes involved in cell growth, proliferation and metabolism [1,2,3], has been implicated in the aetiology of many, perhaps all, human malignancies . MYC levels are tightly regulated in normal cells but a wide range of mutations can override transcriptional and post-transcriptional controls and many provoke over-expression. High levels of MYC provoke apoptosis when cells experience stress from, for example, limited availability of cytokines or nutrients [5,6,7] and this imposes a brake on proliferation . Consequently, anti-apoptotic mutations release that brake and synergise with MYC to promote malignant transformation [9,10,11,12,13,14].
MYC induces apoptosis via the pathway regulated by the BCL-2 family of proteins. BCL-2 and its closest homologues (BCL-XL, BCL-W, MCL-1 and A1/BFL-1) promote cell survival by neutralising pro-apoptotic relatives: BAX and BAK, and more distant relatives known as BH3-only proteins (for recent reviews see [15,16,17]). In healthy cells, BAX and BAK are primarily in an inactive monomeric state and any activated monomers are restrained by the pro-survival proteins. Stress conditions, such as deprivation of cytokines, oncogene expression or DNA damage, provoke up-regulation of pro-apoptotic BH3-only proteins, which bind tightly to the hydrophobic surface groove of pro-survival proteins via their BH3 domains, preventing them from inhibiting BAX and BAK. Certain BH3-only proteins (BIM, tBID, PUMA) can also bind transiently to the analogous surface groove of BAX and BAK, provoking a dramatic conformational change that prompts their homo-dimerisation [18,19,20]. BAX/BAK homo-dimers then aggregate to form homo-oligomeric pores, through which cytochrome c egresses to initiate sequential activation of caspases, which cleave hundreds of vital proteins, thereby dooming the cell.
Chromosome translocations found in Burkitt’s lymphoma and mouse plasmacytomas link the c-MYC gene to Ig gene loci , thereby subjugating MYC expression to strong Ig gene enhancers. Transgenic Eµ-Myc mice developed to model such translocations [22, 23] have greatly advanced our understanding of MYC-driven lymphomagenesis. Overexpression of MYC promotes polyclonal expansion of highly proliferative non-malignant pre-B cells [22,23,24] that are highly susceptible to apoptosis  and progression to malignancy depends upon acquisition of additional synergistic somatic changes such as mutation of RAS  or of the p19ARF/p53 pathway . Of note, lymphomagenesis in these mice is accelerated by overexpression of BCL-2 and other pro-survival homologues [10, 26, 27] or loss of BH3-only proteins BIM [13, 28], PUMA , BMF or BAD .
Different cell types have a greater or lesser dependence on individual pro-survival family members, depending on the relative expression of other BCL-2 family members. Tumour cells are particularly dependent, because they express high levels of BH3-only proteins such as BIM due to the stresses and mutations suffered en route to malignancy [30, 31]. Gene knockout studies have shown that the development and expansion of tumours in Eµ-Myc mice is critically dependent on expression of endogenous MCL-1 [32, 33], BCL-W  and, to a lesser extent, BCL-XL [32, 35] but not BCL-2 .
Understanding of the physiologic importance of pro-survival A1/BFL-1 has lagged due to the fact that the mouse A1 locus contains three very similar functional homologues (A1-a, A1-b and A1-d) and a pseudogene (A1-c) . A1 is expressed in multiple organs in the mouse embryo but apparently only in haemopoietic cells in the adult . Expression in lymphoid and myeloid cells is normally low but is rapidly induced following a variety of stimuli . Mice lacking just the A1-a gene are normal, albeit with some minor defects in their neutrophils and mast cells [39, 40]. Transgenic A1RNAi mice having reduced levels of all functional A1 isoforms have diminished numbers of B cells as well as impaired myelopoiesis and T cell development [41,42,43]. However, recently developed mouse strains lacking all three functional A1 genes are relatively normal, with only minor decreases in γδ T cells, CD4 T cells and conventional dendritic cells [44, 45].
In this study, we have explored the role of A1 in lymphoma development by crossing the A1-a−/− A1-b−/− A1-d−/− mice (hereafter A1−/− mice)  with Eµ-Myc transgenic mice [22, 23]. We also investigated whether A1 was important for the expansion of established Eµ-Myc lymphomas by conditional deletion of a single remaining functional A1 gene in transplanted tumour cells.
A1 expression in mouse lymphoid tumours
Prior to commencing this study, mouse haemopoietic tumours of varying genetic provenance were surveyed for expression of A1 protein, including Eµ-Myc lymphomas, Eµ-Myc/Eµ-Bcl-2 progenitor cell tumours, vavP-MYC T cell lymphomas, Eµ-v-Abl plasmacytomas, p53−/− T lymphomas and MLL-AF9 and AML-ETO myeloid leukaemias (Supplementary Figure S1 and data not shown). Many of the Eµ-Myc lymphomas had readily detectable A1 (Supplementary Figure S1a) but levels were low in most other tumour types except for vavP-MYC T cell lymphomas and some Eµ-v-Abl plasmacytomas. We therefore decided to focus on the Eµ-Myc model to investigate the impact of loss of A1 on tumorigenesis.
Loss of endogenous A1 has no impact on tumour development in Eµ-Myc mice
To generate A1−/− Eµ-Myc mice, two independent lines of A1−/− mice (A1–1 and A1–2)  were crossed with Eµ-Myc mice [22, 23] (all on a C57BL/6 background) and A1+/− Eµ-Myc offspring were then interbred. Cohorts of A1+/+, A1+/− and A1−/− Eµ-Myc mice were then monitored for tumour development and euthanased at ethical endpoint. No significant differences were detected between the A1–1 and A1–2 cohorts (Supplementary Figure S2a) or between males and females (not shown) and so the results have been pooled in all subsequent Figures.
Neither heterozygous nor homozygous loss of A1 had any significant impact on the kinetics of morbidity (Fig. 1a). Phenotypic analysis showed that, as for A1+/+ Eµ-Myc mice, all the tumours in the A1+/− Eµ-Myc and A1−/− Eµ-Myc mice were either B220+sIg−(denoted by pro/pre-B), B220+sIg+ (denoted by B) or a mixture of these phenotypes (denoted by mixed). No significant differences were apparent between genotypes in either the incidence (Fig. 1b) or kinetics (Fig. 1c) of lymphoma type. Furthermore, when sick mice were autopsied, there were no significant differences in the leukaemic burden in the blood and haemopoietic organs (Fig. 1d, Supplementary Figure S2b).
Eµ-Myc-driven tumour development is believed to initiate in the expanded pool of pro and pre-B cells in the bone marrow and spleen of young mice.  To ascertain whether loss of A1 had perturbed the premalignant phenotype, we analysed haemopoietic tissues of healthy young 4-week-old mice using immunostaining and flow cytometry. Consistent with the unchanged kinetics of tumour development, the A1+/+ Eµ-Myc and A1-/- Eµ-Myc mice had comparable numbers of B220+ sIg− cells in the bone marrow and spleen (Fig. 2, Supplementary Table S1). sIg+ B cells and all other major cell populations were also comparable. There were no notable differences between the A1+/+ and A1-/- non-transgenic mice, as also reported elsewhere. 
Immature B lymphoid cells overexpressing MYC are highly susceptible to apoptosis [11,12,13,14]. To determine whether loss of A1 further increased their vulnerability, pro/pre-B cells (B220+sIg−) were isolated from bone marrow using flow cytometry and cultured in vitro without any added cytokines. Analysis over the 48 h-period showed no increase in susceptibility to apoptosis (Fig. 3a).
A1 expression was analysed in pre-malignant pro/pre-B and B cells from healthy young WT and Eµ-Myc mice by western blot analysis (Fig. 3b). A1 was readily apparent in splenic B cells (B220+sIg+), being higher in the WT than the Eµ-Myc transgenic cells. However, it was not detectable in bone marrow pro/pre-B cells (B220+sIg−) of either genotype. These observations differ from those of Sochalska et al.  who, using the same antibody, detected A1 in pre-B as well as B cells and at higher levels in Eµ-Myc than WT populations. The reason for the difference is not clear but could be related to genetic background or other differences (see Discussion). The lack of significant A1 expression in pro/pre-B lymphoid cells in our Eµ-Myc mice would explain why A1+/+ and A1−/− Eµ-Myc pro/pre-B cells did not differ in their sensitivity to apoptosis (Fig. 3a). As previously reported , MCL-1 expression was elevated in the pre-leukaemic Eµ-Myc cells, particularly pro/pre-B cells, where MYC levels are higher than those in sIg+ B cells (Fig. 3b). Loss of A1 did not alter the level of MCL-1 or MYC within comparable cell populations.
To investigate whether changes in the expression of other BCL-2 family members or mutation of the p19ARF/p53 pathway might have compensated for the absence of A1 during lymphomagenesis, western blot analysis was performed. A1 protein was readily detected, at varying levels, in pro/pre-B, B and mixed lymphomas taken from lymph nodes of A1+/+ Eµ-Myc mice (Fig. 4a, b and Supplementary Figure S2c). As in Fig. 3b, however, neither of the control A1+/+ Eµ-Myc premalignant pro/pre-B samples (CD19+ cells from bone marrow) expressed A1 at detectable levels. Thus, either A1 levels increase in pro/pre-B cells during malignant transformation or its expression is dependent on the microenvironment.
MCL-1 was clearly present in all tumours (16/16) (Fig. 4) but, perhaps counter-intuitively, was lower in the A1-/- than the A1+/+ tumours. BCL-2 was readily detectable in 15/16 tumours, at variable levels, and low in all pre-leukaemic samples. BCL-XL was low in all samples except for two A1+/+ Eµ-Myc B lymphomas. Overall, there was no consistent difference in the expression pattern for A1-positive vs. A1-negative cells, for either the pro-survival proteins or for BH3-only proteins PUMA and BIM.
About 30% of Eµ-Myc tumours carry mutations in the p53 pathway [12, 13]. Consistent with this, p53 and/or high p19ARF was evident in 2 of the 16 lymphomas analysed (Fig. 4), one being A1−/− and the other A1+/+.
Taken together, these observations indicate that absence of endogenous A1 has no impact on the kinetics or phenotype of tumour development in Eµ-Myc mice. Although no consistent compensatory changes were detected, this does not rule out the possibility that individual tumours have compensated for the absence of A1 by modulating the expression of different pro- and anti-apoptosis genes.
Loss of A1 confers no disadvantage during competitive repopulation
We next compared the competitive ability of A1+/+ and A1−/− haemopoietic stem and progenitor cells (HSPCs) from Eµ-Myc mice in a bone marrow reconstitution assay. We used UBC-GFP/Eµ-Myc as competitor bone marrow cells mixed in a 1:1 ratio with either A1+/+ Eµ-Myc or A1−/− Eµ-Myc bone marrow cells. The donor cells, which were all Ly5.2, were transplanted into lethally irradiated Ly5.1 recipients and blood was analysed by flow cytometry 6 weeks later. Fig. 5 shows that loss of A1 did not impair the haemopoietic repopulation capacity of Eµ-Myc HSPCs: those from A1−/− Eµ-Myc mice were as competitive as those from A1+/+ Eµ-Myc mice, as both genotypes (GFP−) constituted ~50% of the Ly5.2+ cells in all cell populations analysed, including pre-B and B cells.
Impact of loss of A1 in transplanted lymphomas
Finally, to ascertain whether A1 plays a role in supporting expansion of fully malignant MYC-driven cells in vivo, we undertook conditional deletion in transplanted Eµ-Myc tumours, the strategy used to establish the essential role of MCL-1 for the survival of Eµ-Myc lymphoma cells in vivo . To do so, we first generated Eµ-Myc lymphomas carrying floxed A1-b alleles and an inducible Cre gene, by crossing Eµ-Myc mice with A1-a−/− A1-bfl/fl A1-d−/− (hereafter A1fl/fl) mice  and Rosa26CreERT2 mice (hereafter CreERT2) , which express Cre recombinase that is inactive in the absence of tamoxifen (see Materials and Methods).
When we compared A1 expression levels in premalignant B lymphoid cells from healthy young 4-week-old mice (Supplementary Figure S3a), perhaps not surprisingly, A1 expression was substantially less in the premalignant B cells of A1fl/fl (ie A1-a−/− A1-bfl/fl A1-d−/−) Eµ-MycCreERT2 mice compared to those from A1+/+ Eµ-MycCreERT2 mice and the pro/pre-B cells did not detectably express A1, consistent with the data presented above for premalignant Eµ-Myc pro/pre-B cells (Figs 3b, 4).
Lymphomas arose with comparable kinetics in each of the Eµ-Myc genotypes: A1+/+ Eµ-Myc, A1+/+ Eµ-MycCreERT2, A1fl/+ Eµ-MycCreERT2 and A1fl/fl Eµ-MycCreERT2 (all Ly5.2+) (Supplementary Figure S3b). Multiple lymphomas of each genotype were transplanted intravenously into non-irradiated C57BL/6-Ly5.1 recipients (3 × 106 cells into each of 6 recipients per tumour). On days 5 and 6, three of the recipients were treated with tamoxifen by oral gavage and three received vehicle, then survival was monitored until ethical endpoint (Fig. 6a, Supplementary Figure S3c). Notably, mice transplanted with lymphomas carrying floxed A1-b alleles that were subsequently treated with tamoxifen (red) had a median survival of 6–7 days longer than those treated with vehicle (A1fl/+ Eµ-MycCreERT2, P = 0.0019 and A1fl/fl Eµ-MycCreERT2, P = 0.0075). The implication is that loss of A1 had impaired the expansion of the tumour cells by enhancing apoptosis.
To ascertain whether tamoxifen had indeed induced deletion of the floxed A1-b gene, the tumours that eventually killed the recipients were analysed by PCR. For all tumours analysed (n = 30), A1-b floxed allele(s) were efficiently deleted by tamoxifen activation of CreERT2 (e.g. Fig. 6b).
The development of lymphomas in Eµ-Myc mice is dependent on expression of BCL-2 family members MCL-1 , BCL-XL  and BCL-W but not BCL-2 . This dependence on pro-survival BCL-2 family members is attributed to the increased susceptibility to apoptosis of developing B lymphoid cells in Eµ-Myc mice [11, 12, 49].
Recently, Sochalska et al.  reported that knockdown of all A1 genes did not alter the kinetics of Eµ-Myc lymphomagenesis but, finding that pre-B cells with reduced A1 levels were underrepresented in haemopoietic organs and that the tumours that arose had escaped A1 knockdown, suggested a vital role for A1 in the development of Eµ-Myc lymphomas.
We found no evidence of a requirement for A1 during lymphoma development in Eµ-Myc mice. There was no difference in the onset of tumour-induced morbidity in A1 nullizygous vs. WT Eµ-Myc mice (Fig. 1) and neither was there any alteration in the number of premalignant B lymphoid cells (Fig. 2) or in the repopulating capacity of A1-/- Eµ-Myc haemopoietic stem and progenitor cells (Fig. 5). It is not surprising that premalignant cell numbers were not altered by A1 deletion as we were unable to detect A1 expression in pre-B cells from either WT or Eµ-Myc mice (Fig. 3b). In contrast, A1 expression was readily detectable in pro/pre B lymphoma cells of A1+/+ Eµ-Myc mice (Fig. 4), consistent with the selective pressure observed by Sochalska et al. to maintain A1 during lymphomagenesis .
Differences found in the aspects of the two studies may reflect major differences in the experimental systems. We used germline deleted A1 knockout mice (A1-a−/− A1-b−/− A1-d−/−)  and, during their lengthy stepwise derivation, these mice may well have adapted to lack of A1. In contrast, Sochalska et al. used haemopoietic-specific mosaic expression of transgenic A1 shRNA to constitutively knock down all three functional A1 genes . Furthermore, while the (VV-A1) mice generated by Sochalska et al. had been bred to C57BL/6 mice, residual genetic differences also seem possible, as the line was originally generated and maintained in a C57BL/6 x CBA F1 background . Since A1 expression levels vary with the activation status of B cells [43, 50] differences in the pathogen load within the animal facilities may also have played a role. In this regard we note that the impaired early T-cell differentiation, B cell homoeostasis and granulopoiesis reported for constitutive A1 knockdown  were not observed in the A1 knockout mice derived in our animal facility .
The importance of individual pro-survival BCL-2 family members varies at different stages of Eµ-Myc lymphomagenesis. While BCL-XL expression helps prevent apoptosis during the development of Eµ-Myc lymphomas , it is dispensable for the sustained growth of fully malignant lymphoma cells in transplant recipients . In contrast, MCL-1 is essential for Eµ-Myc lymphomas at both stages [32, 33]. Cognisant of such differences, we also assessed the requirement for A1 during the expansion of established Eµ-Myc lymphoma cells and observed a significant delay in tumour progression of transplanted A1fl/fl Eµ-Myc lymphoma cells following activation of Cre-mediated deletion (P = 0.0075, Fig. 6). In view of the possibility of adaptation to the lower level of A1 in A1-a−/−A1-bfl/flA1-c−/− Eµ-Myc mice (Supplementary Figure S3a), the impact of A1 loss might be even greater should it be possible to simultaneously delete all three functional alleles. Similarly, inhibition of BFL-1, the sole A1 analogue in humans, may have substantial impact.
In summary, taken together with the study by Sochalska et al. , our data suggest that, like MCL-1, BFL-1 is a potential target for the treatment of MYC-driven human tumours. A BFL-1-specific BH3 mimetic should be a useful avenue to pursue, since BFL-1 is overexpressed in a variety of haemopoietic and other malignancies: ALL, CLL, AML, DLBCL, melanoma, stomach and colon cancers and breast cancer .
Materials and methods
Experimental protocols involved in the use of mice were conducted according to the guidelines of the Animal Ethics Committee of the Walter and Eliza Hall Institute (WEHI). All mice were on a C57BL/6 background and bred at WEHI. To generate A1−/− Eµ-Myc mice, Eµ-Myc transgenic males  were crossed with two strains of A1−/− females (A1-1 and A1-2) , and offspring were interbred separately. A1fl/fl Eµ-MycCreERT2 mice were generated by interbreeding Eµ-Myc transgenic males with Rosa26CreERT2 females  and A1fl/fl (A1-a−/− A1-bfl/fl A1-c−/−) females (A1-1 and A1-2) followed by interbreeding of offspring. Genotyping was performed as previously described . Tg(UBC-GFP) 30Scha/J female mice  were bred with Eµ-Myc transgenic males to produce double transgenic offspring. Cohorts of mice were aged to ethical end point or euthanased at 28–30 days of age for premalignant analysis. Ethical endpoint was determined independently by trained animal technicians; criteria included splenomegaly, lymphadenopathy, hind-limb paralysis, hunched stature, weight loss, laboured breathing.
Mice were euthanased according to the guidelines of the Institute’s Animal Ethics Committee. Haemopoietic organs (spleen, inguinal lymph nodes, axillary lymph nodes, brachial lymph nodes, mesenteric lymph node and thymus) were weighed and a peripheral blood sample was collected by either eye bleed or heart bleed. Blood counts and composition were determined using an ADVIA 2120 haematology analyser (Siemens, Erlangen, Germany). Cell suspensions were prepared from lymphomas and cryopreserved. Lymphomas were immunophenotyped by staining with α-B220-APC (clone RA3–6B2), α-IgM−PE (clone 5.1) and α-IgD−FITC (clone 11–26 C) produced in house. Cells were analysed on an LSR II flow cytometer (BD Biosciences) using FlowJo software Version 9.3.2 (TreeStar, Ashland, OR, USA).
Healthy mice were euthanased at 28–30 days of age; their spleen, lymph nodes and thymus were collected and weighed; bone marrow (both femurs) and peripheral blood were also collected. Peripheral blood cell counts were enumerated using an ADVIA 2120 analyser (Siemens). Red blood cells were removed using 0.168 M ammonium chloride. Single cell suspensions were prepared from haemopoietic tissues and cell counts enumerated on a CASY Cell Counter (Scharfe System GmbH, Reutlingen, Germany). Cell composition was determined by immunostaining and flow cytometry (LSR II flow cytometer, BD Biosciences), using FlowJo software and the following fluorochrome-labelled surface marker-specific monoclonal antibodies produced in house: α-CD8-PE (clone YTS169); α-CD4-APC (clone H129.19); α-TCRβ-FITC (clone H57–597); α-B220-PE (clone RA3–6B2); α-IgM-FITC (clone 5.1); α-IgD-FITC (clone 11–26 C); α-IgD-PE; α-CD43-APC (clone S7); α-Mac1-PE (clone M1/70); α-Gr1-APC (clone RB6–8C5); α-Thy1-PE (clone T24/31); α-Ter119-APC.
Pro/pre-B cell survival assay
Bone marrow cells (10 × 106) from 4 week-old mice were stained by incubating with α-B220-PE, α-IgM-FITC and α-IgD-FITC, then washed and resuspended in 4 μg/mL propidium iodide (PI). Viable pro/pre-B cells (B220+IgM-IgD−PI−) were isolated by flow cytometry then cultured at 1 × 106 cells/mL in high-glucose Dulbecco’s Modified Eagle’s medium supplemented with 10% foetal calf serum, 50 μM 2-ME and 100 μM asparagine without additional cytokines to observe spontaneous death. Cell viability was determined at 0, 4, 8, 24, 48 and 72 h by staining with annexin-V-FITC and 4 μg/mL PI followed by analysis on an LSR II flow cytometer.
Western blot analysis
Western blots were performed according to standard procedures using protein lysates prepared from cryopreserved cell pellets using RIPA buffer (300 mM NaCl, 2% IGEPAL CA-630, 1% deoxycholic acid, 0.2% SDS, 100 mM Tris-HCl pH 8.0) containing complete ULTRA protease inhibitors (Roche, Basel, Switzerland). Protein concentration was determined by Bradford assay. Samples (15–20 μg total protein) were run on NuPAGE Bis-Tris gels (Life Technologies) and transferred to nitrocellulose membranes with an iBlot (Life Technologies) according to the manufacturer’s protocol. Membranes were subsequently probed with the following antibodies: A1 (clone 6D6, WEHI mAB lab), BCL-2 (clone 7, BD Biosciences), BCL-XL (clone 44, BD Biosciences), MCL-1 (clone 19C4–15, WEHI mAb lab), PUMA (polyclonal, Abcam), BIM (clone 3C5, WEHI mAb lab), p53 (FL-393, Santa Cruz Biotechnology, Santa Cruz, CA, USA), p19ARF (p19ARF exon 2, Rockland, Gilbertsville, PA, USA), c-MYC (D84C12, Cell Signaling Techology, Danvers, MA, USA) and β-ACTIN (clone AC-74, Sigma-Aldrich). Blots were visualised using LuminataTM Forte western HRP substrate (Merck-Millipore) on a ChemiDoc Touch (Bio-Rad, Hercules, CA, USA) and analysed using Image Lab software (Bio-Rad).
Haemopoietic competitive reconstitution
Bone marrow was collected from 4-week-old female UBC-GFP/Eµ-Myc, A1+/+ Eµ-Myc and A1−/− Eµ-Myc mice and resuspended in phosphate buffered saline to 15 × 106/mL. UBC-GFP/Eµ-Myc cells were mixed at a 1:1 ratio with A1+/+ Eµ-Myc or A1−/− Eµ-Myc cells and 3 × 106 cells were injected into lethally irradiated (2 × 5.5 Gy spaced by 2 h) C57BL/6-Ly5.1 mice. For each competitive bone marrow mixture, 3 recipient mice were used. To prevent infections, transplanted animals were initially provided with water containing neomycin (Sigma). Six weeks later, when their haemopoietic system had re-established, blood was collected from the retro-orbital plexus for ADVIA and FACS analysis.
Conditional A1 deletion in transplanted lymphomas
Lymphomas originating from A1+/+ Eµ-Myc, A1+/+ Eµ-MycCreERT2, A1fl/+ Eµ-MycCreERT2 and A1fl/fl Eµ-MycCreERT2 female mice were cryopreserved as cell suspensions for later use. Tumour cells were thawed and resuspended at 15 × 106 cells/mL in PBS, then 3 × 106 cells (200 µL) injected into the tail veins of 6 female C57BL/6-Ly5.1 recipient mice (unirradiated). On d5 and d6 post-transplantation, 3 out of 6 mice were treated with 200 mg tamoxifen/kg body weight (Sigma-Aldrich) in peanut oil/10% ethanol by oral gavage, while the remaining 3 mice received only vehicle (peanut oil/10% ethanol). Any transplantations deemed unsuccessful (i.e. the vehicle-treated mice did not all become sick at a similar time) were excluded from analysis. When transplanted mice reached ethical endpoint, they were euthanased and their lymphomas cryopreserved as single-cell suspensions for later use. Lymphoma cells were thawed and stained with α-Ly5.1-APC (A20.1) and α-Ly5.2-PE (S-450–15.2). Viable donor-derived (Ly5.2+PI−) tumour cells were purified by flow cytometry and DNA was isolated using a DNeasy Qiagen kit and analysed for A1-b, A1-d, Eµ-Myc and Rosa26CreER genes by PCR and gel electrophoresis.
GraphPad Prism (GraphPad Software Inc.) was used to graph and statistically analyse data. For analysis of Kaplan–Meier mouse survival curves, significance was determined using the log−rank (Mantel-Cox) test. Ordinary one-way ANOVA with Tukey’s multiple comparisons test or Student’s T-test was used for statistical analysis; P values <0.05 were considered to be statistically significant.
Suzanne Cory and Cassandra J. Vandenberg are Joint senior authors.
We thank K Hughes, C D’Alessandro, G Siciliano, J Corbin, J McManus and T Nikolaou for technical assistance; K Campbell, A Delbridge and S Glaser for tumour samples; and the institute’s flow cytometry facility for skilled support. This work was supported by funding from the NHMRC (Australia) program grant 1016701; US Leukaemia and Lymphoma Society Specialized Center for Research Grant 7001–13; and infrastructure support to the institute from the NHMRC Independent Research Institute Infrastructure Support Scheme (IRISS 9000220) and the Victorian State Government Operational Infrastructure Support (OIS).
CJV and SC conceived the studies, planned experiments, analysed the data and wrote the manuscript. MM, NSA, MR and CJV performed the experiments and analysed the data. RLS and MJH provided the mice and intellectual input.